Bronchoalveolar lavage findings in HTLV-I carriers and HAM/TSP patients
| Subjects | Cell count(×105/ml) | AM (%) | Ly (%) | Neu (%) | Eo (%) | CD4+ cells (%) | CD8+ cells (%) | CD4/CD8 |
|---|---|---|---|---|---|---|---|---|
| Data are shown as median (range). | ||||||||
| N, number of subjects; AM, alveolar macrophage; Ly, lymphocyte; Neu, neutrophil; Eo, eosinophil; HTLV-I, human T lymphotropic virus type I; AHCs, asymptomatic HTLV-I carriers; SHCs, symptomatic HTLV-I carriers with chronic inflammatory diseases of respiratory tract; HAM/TSP, HTLV-I-associated myelopathy/tropical spastic paraparesis. | ||||||||
| *p<0.05, **p<0.01 compared with control subjects. | ||||||||
| †The cell differential in BAL fluid was determined in 30 HTLV-I carriers (15 AHCs and 15 SHCs) and T lymphocyte subsets were determined in 22 HTLV-I carriers (11 AHCs and 11 SHCs). | ||||||||
| HTLV-I carriers | 1.2** | 87.6 | 11.0 | 0.8 | 0.0 | 53.3 | 28.8 | 1.9 |
| N = 30 (22)† | (0.4–5.8) | (42.5–97.4) | (2.6–55.3) | (0.0–25.0) | (0.0–1.2) | (37.1–75.6) | (13.4–55.2) | (0.8–5.6) |
| AHCs | 1.0* | 88.2 | 10.5 | 0.8 | 0.1 | 53.0 | 26.9 | 2.1* |
| N = 15 (11)† | (0.4–2.8) | (70.5–96.4) | (3.2–28.6) | (0.3–1.6) | (0.0–0.5) | (42.8–75.6) | (13.4–39.5) | (1.1–5.6) |
| SHCs | 1.5** | 87.0 | 11.4 | 0.7 | 0.0 | 55.8 | 31.7 | 1.5 |
| N = 15 (11)† | (0.5–5.8) | (42.5–97.4) | (2.6–55.3) | (0.0–25.0) | (0.0–1.2) | (37.1–71.7) | (21.1–55.2) | (0.8–2.8) |
| HAM/TSP | 2.2** | 52.9** | 46.4** | 1.1 | 0.0 | 48.7 | 47.6* | 1.0 |
| N = 8 | (1.4–4.0) | (27.0–73.4) | (21.0–71.9) | (0.0–13.4) | (0.0–0.5) | (33.1–76.2) | (20.4–61.0) | (0.5–3.7) |
| Controls | 0.6 | 91.2 | 8.4 | 0.6 | 0.1 | 48.7 | 31.4 | 1.5 |
| N = 9 | (0.3–1.0) | (87.9–95.8) | (3.8–10.5) | (0.2–1.3) | (0.0–0.4) | (33.4–59.5) | (22.7–45.1) | (0.9–2.1) |